Pacer Advisors Inc. Makes New Investment in Theravance Biopharma, Inc. $TBPH

Pacer Advisors Inc. bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 338,958 shares of the biopharmaceutical company’s stock, valued at approximately $6,342,000.

Several other hedge funds and other institutional investors also recently modified their holdings of TBPH. Arrowstreet Capital Limited Partnership bought a new position in shares of Theravance Biopharma during the third quarter worth about $10,611,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Theravance Biopharma in the 3rd quarter worth about $4,536,000. Janus Henderson Group PLC lifted its position in Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after purchasing an additional 273,288 shares during the last quarter. Two Sigma Investments LP boosted its stake in Theravance Biopharma by 1,199.9% during the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock valued at $3,377,000 after purchasing an additional 213,480 shares during the period. Finally, HRT Financial LP boosted its stake in Theravance Biopharma by 892.8% during the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after purchasing an additional 209,397 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on TBPH. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Oppenheimer cut Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. BTIG Research reiterated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. B. Riley Financial increased their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. Finally, HC Wainwright raised their target price on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Theravance Biopharma currently has a consensus rating of “Hold” and an average price target of $21.40.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $16.58 on Monday. The stock has a market cap of $854.70 million, a P/E ratio of 7.54 and a beta of 0.17. The firm’s 50-day simple moving average is $16.50 and its 200 day simple moving average is $17.35. Theravance Biopharma, Inc. has a fifty-two week low of $10.44 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, sell-side analysts anticipate that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the transaction, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is owned by company insiders.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.